human PD-L1, His-Tag

€320.00

Shipping calculated at checkout

trenzyme SKU: P2020-164_100

Available Now!

Size: 100µg

Need a quote for an individual request or for a bulk order? Please contact us

Description

Programmed death ligand 1 (PD-L1) is considered as crucial immune checkpoint regulator with significant implications in cancer and autoimmune diseases. Binding to its receptor, programmed cell death protein 1 (PD-1), provides inhibitory signals that modulate T cell activation and ensure maintenance of peripheral tolerance. Cancer cells often exploit the PD-L1/PD-1 pathway to evade immune surveillance. Overexpression of PD-L1 allows cancer cells to inhibit anti-tumor immune responses, leading to immune escape and tumor progression. PD-L1 expression in the tumor microenvironment has become a critical biomarker for predicting responses to immunotherapy.

Cartoon laboratory scientist Jelly the Cellebrity in a white lab coat holding a flask with liquid and pointing upward
  • Product Name: human PD-L1, His-Tag
  • Catalog No.: P2020-164
  • RefSeq Links: HGNC:17635; NX_Q9NZQ7; NP_054862.1; NM_014143.3; PDBe 7xae; UniProt: Q9NZQ7
  • Synonyms: Programmed cell death 1 ligand 1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1
  • Species: Homo sapiens
  • Tags: His-tag, C-terminal
  • Sequence without tags (AA 19-239):
    MFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQ
    HSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKI
    NQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTL
    RINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERT
  • Expression Host: HEK293
  • Formulation: PBS; pH 7.4
  • Format: Liquid, stored and shipped at -80° C
  • Purity: > 95 % as determined by SDS-PAGE
  • Application: ELISA, WB, Functional assay

Programmed death ligand 1 (PD-L1), also known as B7 homolog 1 (B7-H1), is a transmembrane glycoprotein, which belongs to the B7 family of immune molecules and plays a pivotal role in regulating adaptive immune responses. Various stimuli, including inflammatory signals and interferon-gamma (IFN-ɣ), induce the expression of PD-L1 on antigen-presenting cells (APCs), such as dendritic cells, macrophages and B cells in peripheral tissues, as well as on epithelial and vascular endothelial cells. Its receptor, programmed cell death protein 1 (PD-1), which is expressed on activated T cells, recognizes PD-L1. This interaction serves as negative feedback mechanism to modulate T cell activation and to prevent excessive immune responses, contributing to immune homeostasis. Apparently, dysregulation of PD-L1 expression or function leads to the development of autoimmune diseases, such as rheumatoid arthritis. Tumor cells evade immune surveillance due to overexpression of PD-L1 on various cancer cell types. This enables inhibition of anti-tumor immune responses and promotes tumor growth and progression. PD-L1 expression in the tumor microenvironment has become a critical biomarker for predicting responses to immunotherapy. Immune checkpoint inhibition using monoclonal antibodies blocking the PD-1/PD-L1 interaction has emerged as excellent therapeutic strategy in cancer therapy. Further insights into PD-L1 biology will likely lead to improved treatment modalities and expanded applications in the field of immune-mediated diseases.


SDS-PAGE/Coll. Coomassie

Histogram of marked lane in gel picture

SDS-Page of human PD-L1, His-Tag
Histogram of human PD-L1, His-Tag

Questions? Ask Zymi.

Zymi is trenzyme’s AI-powered assistant, here to help you find relevant information about our products and services.

Chat with Zymi

Do you need a quote for an individual request or a bulk order?

Contact Us